Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1712-1722

  Mahoney Jr , Donald H ^a   Shuster, Jonathan J ^a   Nitschke, Ruprecht ^a   Lauer, Stephen J ^a   Steuber, C Philip ^a   Winick, Naomi ^a   Camitta, Bruce ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BRAIN CALCIFICATION; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0344542098     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1712     Document Type: Article

References (56)

1. Pinkel D, Woo S: Prevention and treatment of meningeal leukemia in children. Blood 84:355-366, 1994
2. Pui C-H: Childhood leukemias. N Engl J Med 332:1618-1630, 1995
3. Veerman AJP, Hahlen K, Kamps WA, et al: High cure rate with a moderately intensive treatment regimen in non - high risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911-918, 1996
4. Conter V, Arico M, Valsecchi MG, et al: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster - based intensive chemotherapy. J Clin Oncol 13:2497-2502, 1995
5. Ochs JJ: Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 11:93-105, 1989
6. DiMario FJ, Packer RJ: Acute mental status changes in children with systemic cancer. Pediatrics 85:353-360, 1990
7. Ochs JJ, Bowman WP, Pui C-H, et al: Seizures in childhood lymphoblastic leukaemia patients. Lancet 2:1422-1424, 1984
8. Peylan-Remu N, Poplack DG, Pizzo PA, et al: Abnormal computed tomography of the brain in asymptomatic children with acute lymphocytic leukemia following central nervous system prophylaxis. N Engl J Med 294:815-818, 1978
9. Brouwers P, Poplack D: Memory and learning sequelae in long-term survivors of acute lymphoblastic leukemia: Association with attention deficits. Am J Pediatr Hematol Oncol 12:174-181, 1990
10. Mahoney DH, Shuster J, Nitschke R, et al: Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group Phase III Trial. J Clin Oncol 116:246-254, 1998
11. Mahoney DH, Camitta B, Leventhal BG, et al: Repetitive low-dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. Cancer 75:2623-2631, 1995
12. Packer RJ, Zimmerman RA, Bilaniuk LT: Magnetic resonance imaging in the evaluation of treatment-related central nervous system damage. Cancer 58:635-640, 1986
13. Riccardi R, Brouwers P, DiChiro A, Poplack DG: Abnormal computed tomography brain scans in children with acute lymphoblastic leukemia: Serial long-term follow-up. J Clin Oncol 3:12-19, 1985
14. Metha C, Patel N: STAT Xact 3 for Windows. Cytel Software Corp, Cambridge, MA, 1995
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials required prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
17. Camitta B, Leventhal B, Lauer S, et al: Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 7:1539-1544, 1989
18. Maytal J, Grossman R, Yusuf FH, et al: Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. Epilepsia 36:831-836, 1995
19. Chessells JM, Cox TCS, Kendall B, et al: Neurotoxicity in lymphoblastic leukaemia: Comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child 65:416-422, 1990
20. Ochs JJ, Mulhern R, Fairclough D, et al: Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol 9:145-151, 1991
21. Waber DP, Tarbell NJ, Fairclough D, et al: Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: Cranial radiation requires an accomplice. J Clin Oncol 13:2490-2496, 1995
22. MacLean WE, Noll RB, Stehbens JA, et al: Neuropsychological effects of cranial irradiation in young children with acute lymphoblastic leukemia 9 months after diagnosis. The Children's Cancer Group. Arch Neurol 52:156-160, 1995
23. Mulhern RK, Wasserman AL, Fairclough D, Ochs J: Memory function in disease-free survivors of childhood acute lymphocytic leukemia given CNS prophylaxis with or without 1,800 cGy cranial irradiation. J Clin Oncol 6:315-320, 1988
24. Ochs JJ, Parvey LS, Whitaker JN, et al: Serial cranial computed tomography scans in children with leukemia given two different forms of central nervous system therapy. J Clin Oncol 1:793-799, 1983
25. McIntosh S, Fischer DB, Rothman SG, et al: Intracranial calcifications in childhood leukemia. Pediatrics 91:909-913, 1977
26. Lasorella A, Petrone A, Colosimo C, et al: High incidence of cerebral calcifications associated with increasing amount of intrathecal methotrexate in children with ALL. Proc Am Soc Clin Oncol 12:A1065, 1993 (abstr)
27. Rowland JH, Glidewell OJ, Sibley RF, et al: Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukemia. J Clin Oncol 2:1327-1335, 1984
28. Butler RW, Hill JM, Steinherz PG, et al: Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol 12:2612-2629, 1994
29. Abromowitch M, Ochs J, Pu C-H, et al: High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St Jude Total Study X. Med Pediatr Oncol 16:297-303, 1988
30. Yim YS, Mahoney DH, Oshman DG: Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 67:2058-2061, 1991
31. Walker RW, Allen JC, Rosen G, Caparros B: Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 4:1845-1850, 1986
32. Kingma A, Mooyaart EL, Kamps WA, et al: Magnetic resonance imaging of the brain and neuropsychological evaluation in children treated for acute lymphoblastic leukemia at a young age. Am J Pediatr Hematol Oncol 15:231-238, 1993
33. Matsumoto K, Takahashi S, Sato A, et al: Leukoencephalopathy in childhood hematopoietic neoplasm caused by moderate dose methotrexate and prophylactic cranial radiotherapy - An MR analysis. Int J Radiat Oncol Biol Phys 32:913-918, 1995
34. Hasle H, Helgestad J, Christensen JK, et al: Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukemia: Long-term follow-up with cerebral computed tomography scans and endocrinological studies. Euro J Pediatr 154:24-29, 1995
35. Paakko E, Vainionpaa L, Lanning M, et al: White matter changes in children treated for acute lymphoblastic leukemia. Cancer 70:2728-2733, 1992
36. Asato R, Akiyama Y, Ito M, et al: Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer 70:1997-2004, 1992
37. Bakke SJ, Fossen A, Storm-Mathiesen I, Lie SO: Long-term cerebral effects of CNS chemotherapy in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 10:267-270, 1993
38. Brown RT, Madan-Swain A, Pais R, et al: Chemotherapy for acute lymphocytic leukemia: Cognitive and academic sequelae. J Pediatr 121:885-889, 1992
39. Copeland DR, Moore BD, Francis DJ, et al: Neuropsychologic effects of chemotherapy on children with cancer: A longitudinal study. J Clin Oncol 14:2826-2835, 1996
40. Wilson DA, Nitschke R, Bowman ME, et al: Transient white matter changes on MR images in children undergoing chemotherapy for acute lymphocytic leukemia: Correlation with neuropsychologic deficiencies. Radiology 180:205-209, 1991
41. Winick NJ, Bowman WP, Kamen BA, et al: Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 84:252-256, 1992
42. Pullen J, Boyett J, Shuster J, et al: Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11:839-849, 1993
43. Land VJ, Shuster JJ, Crist WM, et al: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1939-1945, 1994
44. Quinn CT, Kamen BA: A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Invest Med 44:522-530, 1996
45. Broxson EH, Stork LC, Allen RH, et al: Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 49:5879-5883, 1989
46. Quinn CT, Griener JC, Bottiglieri T, et al: Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for treatment of cancer. J Clin Oncol 15:2800-2806, 1997
47. Quinn CT, Griener JC, Bottiglieri T, Kamen BA: Methotrexate, homocysteine, and seizures. J Clin Oncol 16:393-394, 1998
48. Brattstrom LE, Israelsson B, Jeppson JO, et al: Folic acid - An innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48:215-221, 1988
49. Thyss A, Milano G, Etienne MC, et al: Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer 59:627-630, 1989
50. Bell B, Abish S, Shuster J, et al: Neurotoxicity (NT) in patients with standard risk acute lymphoblastic leukemia (ALL) on Pediatric Oncology Group (POG) 9405: A preliminary report. Blood 90:559A, 1997 (abst)
51. Eden OB, Goldie W, Wood T, Etucubanas E: Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemia. Cancer 42:53-58, 1978
52. VonderWeid N, deCrousaz H, Beck D, et al: Acute fatal myeloencephalopathy after combined intrathecal chemotherapy in a child with acute lymphoblastic leukemia. Med Pediatr Oncol 19:192-198, 1991
53. Dunton SF, Nitschke R, Spruce WE, et al: Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study. Cancer 57:1083-1088, 1986
54. Bleyer W, Dedrich R: Clinical pharmacology of intrathecal methotrexate pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61:703-708, 1977
55. Bleyer WA, Nelson A, Kamen BA: Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hemat Oncol 19:530-532, 1997
56. Graham ML, Shuster JJ, Kamen BA, et al: Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: A Pediatric Oncology Group study. Clin Cancer Res 2:331-337, 1996